| 2026年中报 | 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 原料药业务(元) | 228,576,033.58 | 471,804,791.39 | 207,275,090.20 | 410,716,865.23 | 181,914,375.98 |
| 制剂业务(元) | 4,539,046.38 | 11,359,863.55 | 4,865,651.28 | 11,654,559.77 | 5,409,497.31 |
| 中间体业务(元) | 15,926,166.93 | 46,454,234.61 | 28,760,815.93 | 46,830,986.22 | 22,253,143.30 |
| 其他(元) | - | 2,640,489.91 | 1,184,302.93 | 2,307,751.13 | 1,059,828.50 |
| 其他业务(元) | 1,849,092.66 | - | - | - | - |
| 营业成本(元) | |||||
| 原料药业务(元) | 122,669,660.13 | 258,498,471.12 | 115,399,734.73 | 244,345,112.78 | 108,617,015.13 |
| 制剂业务(元) | 2,613,885.96 | 4,808,559.45 | 2,174,682.82 | 5,171,086.60 | 2,095,523.28 |
| 中间体业务(元) | 7,146,885.10 | 22,689,950.64 | 15,119,325.38 | 23,095,251.36 | 12,093,480.13 |
| 其他(元) | - | 3,552,184.46 | 1,606,114.54 | 3,352,091.91 | 1,549,903.54 |
| 其他业务(元) | 1,605,069.78 | - | - | - | - |
| 毛利(元) | |||||
| 原料药业务(元) | 105,906,373.45 | 213,306,320.27 | 91,875,355.47 | 166,371,752.45 | 73,297,360.85 |
| 制剂业务(元) | 1,925,160.42 | 6,551,304.10 | 2,690,968.46 | 6,483,473.17 | 3,313,974.03 |
| 中间体业务(元) | 8,779,281.83 | 23,764,283.97 | 13,641,490.55 | 23,735,734.86 | 10,159,663.17 |
| 其他(元) | - | -911,694.55 | -421,811.61 | -1,044,340.78 | -490,075.04 |
| 其他业务(元) | 244,022.88 | - | - | - | - |
| 毛利率(%) | |||||
| 原料药业务(%) | 46.33 | 45.21 | 44.33 | 40.51 | 40.29 |
| 制剂业务(%) | 42.41 | 57.67 | 55.31 | 55.63 | 61.26 |
| 中间体业务(%) | 55.12 | 51.16 | 47.43 | 50.68 | 45.65 |
| 其他(%) | - | -34.53 | -35.62 | -45.25 | -46.24 |
| 其他业务(%) | 13.20 | - | - | - | - |
| 收入构成(%) | |||||
| 原料药业务(%) | 91.11 | 88.64 | 85.62 | 87.11 | 86.36 |
| 制剂业务(%) | 1.81 | 2.13 | 2.01 | 2.47 | 2.57 |
| 中间体业务(%) | 6.35 | 8.73 | 11.88 | 9.93 | 10.56 |
| 其他(%) | - | 0.50 | 0.49 | 0.49 | 0.50 |
| 其他业务(%) | 0.74 | - | - | - | - |
| 毛利构成(%) | |||||
| 原料药业务(%) | 90.63 | 87.89 | 85.24 | 85.08 | 84.95 |
| 制剂业务(%) | 1.65 | 2.70 | 2.50 | 3.32 | 3.84 |
| 中间体业务(%) | 7.51 | 9.79 | 12.66 | 12.14 | 11.78 |
| 其他(%) | - | -0.38 | -0.39 | -0.53 | -0.57 |
| 其他业务(%) | 0.21 | - | - | - | - |